# Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion

> **NCT04617054** · PHASE2 · TERMINATED · sponsor: **Nuvation Bio Inc.** · enrollment: 14 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** AB-106

## Key facts

- **NCT ID:** NCT04617054
- **Lead sponsor:** Nuvation Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-01
- **Primary completion:** 2024-12-06
- **Final completion:** 2024-12-06
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** The study was discontinued early by the Sponsor for business reasons on 06 Dec 2024
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04617054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04617054, "Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT04617054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*